Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study
<p dir="ltr">We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favip...
محفوظ في:
مواد مشابهة
-
Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis
حسب: Reem Hasan Elajez (22504292)
منشور في: (2025) -
Ischemic stroke in the setting of supratherapeutic International Normalized Ratio following coronavirus disease 2019 infection: a case report
حسب: Gokhan Demir (10366814)
منشور في: (2023) -
Remdesivir therapy causing bradycardia in COVID-19 patients: Two case reports
حسب: Alaaeldin Abdelmajid (12535542)
منشور في: (2021) -
The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review
حسب: Nasrallah, Gheyath K.
منشور في: (2020) -
Empiric antibiotic therapy of community-acquired Pneumonia at the American University of Beirut Medical Center. (c2001)
حسب: Cherfan, Antoine
منشور في: (2001)